Chronic, recurrent Lymphocytic Leukemia Not Yet Recruiting Phase 2 Trials for Obinutuzumab (DB08935)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs